• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

青少年肌萎缩性侧索硬化症的临床与遗传学研究进展:曙光初现。

Clinical and Genetic Aspects of Juvenile Amyotrophic Lateral Sclerosis: A Promising Era Emerges.

机构信息

Motor Neuron Disease Unit, Division of Neuromuscular Diseases, Federal University of Sao Paulo (UNIFESP), Sao Paulo 04039-060, Brazil.

出版信息

Genes (Basel). 2024 Feb 28;15(3):311. doi: 10.3390/genes15030311.

DOI:10.3390/genes15030311
PMID:38540369
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10969870/
Abstract

Juvenile Amyotrophic Lateral Sclerosis is a genetically heterogeneous neurodegenerative disorder, which is frequently misdiagnosed due to low clinical suspicion and little knowledge about disease characteristics. More than 20 different genetic have been associated with both sporadic and familial juvenile Amyotrophic Lateral Sclerosis. Currently, almost 40% of cases have an identifiable monogenic basis; type 6, associated with gene variants, is the most prevalent globally. Despite several upper motor neuron-dominant forms being generally associated with long-standing motor symptoms and slowly progressive course, certain subtypes with lower motor neuron-dominant features and early bulbar compromise lead to rapidly progressive motor handicap. For some monogenic forms, there is a well-established genotypic-phenotypic correlation. There are no specific biochemical and neuroimaging biomarkers for the diagnosis of juvenile Amyotrophic Lateral Sclerosis. There are several inherited neurodegenerative and neurometabolic disorders which can lead to the signs of motor neuron impairment. This review emphasizes the importance of high clinical suspicion, assessment, and proper diagnostic work-up for juvenile Amyotrophic Lateral Sclerosis.

摘要

青少年肌萎缩侧索硬化症是一种遗传异质性的神经退行性疾病,由于临床怀疑低和对疾病特征的了解甚少,常被误诊。超过 20 种不同的基因与散发性和家族性青少年肌萎缩侧索硬化症有关。目前,几乎 40%的病例有可识别的单基因基础;全球最常见的是与 基因变异相关的 6 型。尽管几种以上运动神经元占优势的形式通常与长期运动症状和缓慢进展过程有关,但某些以下运动神经元占优势特征和早期延髓损害的亚型会导致进行性运动障碍。对于某些单基因形式,存在明确的基因型-表型相关性。目前还没有用于诊断青少年肌萎缩侧索硬化症的特定生化和神经影像学生物标志物。有几种遗传性神经退行性和神经代谢性疾病可导致运动神经元损伤的迹象。本综述强调了对青少年肌萎缩侧索硬化症进行高度临床怀疑、评估和适当诊断的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/489e/10969870/4487075219e8/genes-15-00311-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/489e/10969870/4487075219e8/genes-15-00311-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/489e/10969870/4487075219e8/genes-15-00311-g001.jpg

相似文献

1
Clinical and Genetic Aspects of Juvenile Amyotrophic Lateral Sclerosis: A Promising Era Emerges.青少年肌萎缩性侧索硬化症的临床与遗传学研究进展:曙光初现。
Genes (Basel). 2024 Feb 28;15(3):311. doi: 10.3390/genes15030311.
2
Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity.轻度运动障碍作为肌萎缩侧索硬化症的前驱状态:一种新的诊断实体。
Brain. 2022 Oct 21;145(10):3500-3508. doi: 10.1093/brain/awac185.
3
Juvenile Amyotrophic Lateral Sclerosis: A Review.青少年型肌萎缩侧索硬化症:综述。
Genes (Basel). 2021 Nov 30;12(12):1935. doi: 10.3390/genes12121935.
4
Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.伴有 C9ORF72 基因扩增的肌萎缩侧索硬化症的临床病理特征。
Brain. 2012 Mar;135(Pt 3):751-64. doi: 10.1093/brain/awr365.
5
Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis.广泛的灰质病变在肌萎缩侧索硬化症的纵向脑部磁共振成像和临床情况中占主导地位。
Brain. 2014 Sep;137(Pt 9):2546-55. doi: 10.1093/brain/awu162. Epub 2014 Jun 20.
6
Genotype-phenotype correlation in seven motor neuron disease families with novel ALS2 mutations.七种携带新型 ALS2 突变的运动神经元病家系的基因型-表型相关性研究。
Am J Med Genet A. 2021 Feb;185(2):344-354. doi: 10.1002/ajmg.a.61951. Epub 2020 Nov 5.
7
A rare case of juvenile amyotrophic lateral sclerosis.一例罕见的青少年肌萎缩侧索硬化症。
Turk J Pediatr. 2021;63(3):495-499. doi: 10.24953/turkjped.2021.03.017.
8
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.预防肌萎缩侧索硬化症:前驱神经退行性疾病的启示。
Brain. 2022 Mar 29;145(1):27-44. doi: 10.1093/brain/awab404.
9
Clinical and genetic basis of familial amyotrophic lateral sclerosis.家族性肌萎缩侧索硬化症的临床与遗传基础
Arq Neuropsiquiatr. 2015 Dec;73(12):1026-37. doi: 10.1590/0004-282X20150161. Epub 2015 Oct 13.
10
A molecular genetic approach to amyotrophic lateral sclerosis.肌萎缩侧索硬化症的分子遗传学研究方法。
Int J Neurol. 1991;25-26:60-9.

引用本文的文献

1
Genetic and functional analyses of SPTLC1 in juvenile amyotrophic lateral sclerosis.青少年肌萎缩侧索硬化症中SPTLC1的遗传与功能分析
J Neurol. 2024 Dec 12;272(1):36. doi: 10.1007/s00415-024-12776-5.

本文引用的文献

1
Recurrent mutation in confirms dysregulated sphingolipid production to cause juvenile amyotrophic lateral sclerosis.重复突变导致鞘脂代谢失调,从而引发少年型肌萎缩侧索硬化症。
J Neurol Neurosurg Psychiatry. 2024 Feb 14;95(3):201-205. doi: 10.1136/jnnp-2023-332130.
2
Recurrent de novo variant causes childhood-onset amyotrophic lateral sclerosis (ALS) by excess sphingolipid synthesis.反复出现的新生变异通过过量合成神经酰胺引起儿童发病的肌萎缩侧索硬化症(ALS)。
J Neurol Neurosurg Psychiatry. 2024 Jan 11;95(2):103-113. doi: 10.1136/jnnp-2023-332132.
3
Association of TRMT2B gene variants with juvenile amyotrophic lateral sclerosis.
TRMT2B 基因变异与青少年肌萎缩侧索硬化症的关联。
Front Med. 2024 Feb;18(1):68-80. doi: 10.1007/s11684-023-1005-y. Epub 2023 Oct 24.
4
Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.对以下内容的勘误:在临床症状前SOD1基因变异携带者中开展的一项托弗生(tofersen)随机、安慰剂对照3期试验的设计:ATLAS研究。
Neurotherapeutics. 2022 Sep;19(5):1686. doi: 10.1007/s13311-022-01286-9.
5
Trial of Antisense Oligonucleotide Tofersen for ALS.针对肌萎缩侧索硬化症的反义寡核苷酸药物 Tofersen 的试验。
N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705.
6
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.Tofersen 治疗临床前 SOD1 变异携带者的随机、安慰剂对照、3 期临床试验设计:ATLAS 研究。
Neurotherapeutics. 2022 Jul;19(4):1248-1258. doi: 10.1007/s13311-022-01237-4. Epub 2022 May 18.
7
InFUSing antisense oligonucleotides for treating ALS.用反义寡核苷酸治疗肌萎缩侧索硬化症。
Trends Mol Med. 2022 Apr;28(4):253-254. doi: 10.1016/j.molmed.2022.02.006. Epub 2022 Mar 1.
8
Clinical trials in pediatric ALS: a TRICALS feasibility study.儿科肌萎缩侧索硬化症临床试验:TRICALS 可行性研究。
Amyotroph Lateral Scler Frontotemporal Degener. 2022 Nov;23(7-8):481-488. doi: 10.1080/21678421.2021.2024856. Epub 2022 Feb 16.
9
Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.反义寡核苷酸沉默 FUS 表达作为肌萎缩侧索硬化症的治疗方法。
Nat Med. 2022 Jan;28(1):104-116. doi: 10.1038/s41591-021-01615-z. Epub 2022 Jan 24.
10
Juvenile Amyotrophic Lateral Sclerosis: A Review.青少年型肌萎缩侧索硬化症:综述。
Genes (Basel). 2021 Nov 30;12(12):1935. doi: 10.3390/genes12121935.